Tyro3 Targeting as a Radiosensitizing Strategy in Bladder Cancer through Cell Cycle Dysregulation

Silina, Linda; Dufour, Florent; Rapinat, Audrey; Réyès, Cécile; Gentien, David; Maksut, Fatlinda; Radvanyi, François; Verrelle, Pierre; Bernard‐Pierrot, Isabelle; Mégnin-Chanet, Frédérique

doi:10.3390/ijms23158671

Cited by 4 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies depicted that the aberrant TYRO3 expression in tumor cells effectively enhances the proliferation and migration of tumor cells [ 22 , 23 ]. Therefore, the expression of TYRO3 would be aberrantly activated with tumorigenesis and metastasis.…”

Section: Resultsmentioning

confidence: 99%

TYRO3 promotes tumorigenesis and drug resistance in colorectal cancer by enhancing the epithelial-mesenchymal transition process

Shao

Sun

Zhong

et al. 2023

Aging

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide. Although considerable advances in CRC treatment have been achieved, effective treatment improvement has hit a bottleneck. This study demonstrated that TYRO3 expression was aberrantly increased in CRC tissues with prognosis association. The prediction model of prognosis for CRC patients was constructed based on TYRO3 expression. The model suggested that the TYRO3 level is crucial to the final prediction results. We observed that knockdown TYRO3 expression could inhibit the proliferation and migration ability and reverse the drug resistance by constructing drug-resistant CRC cell lines. In vivo experiments also confirmed this conclusion. Thus, targeting TYRO3 combined with 5-Fu treatment could provide a better therapeutic effect. Additionally, TYRO3 could inhibit the EMT process by down-regulating ENO1, which may be achieved by interfering with energy metabolism in cancer cells. Therefore, the current study provides a theoretical basis for TYRO3 in drug-resistance of CRC cells and highlights a new strategy for CRC-targeted therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

TYRO3 promotes tumorigenesis and drug resistance in colorectal cancer by enhancing the epithelial-mesenchymal transition process

Shao

Sun

Zhong

et al. 2023

Aging

View full text Add to dashboard Cite

show abstract

“…TYRO3 has been considered carcinogenic and a potential therapeutic target for GC, 13,14 whereas studies have indicated the role of TYRO3 in other solid tumors. 15,16 Regarding the combined regulatory role of the TAM family in tumorigenesis and tumor development, targeting aberrant TYRO3 expression in GC may be a new cancer treatment strategy. A study reported that TYRO3 regulated colorectal cancer cell proliferation, migration, and invasion through the AKT-mTOR pathway.…”

mentioning

confidence: 99%

Overexpression of TYRO3 indicates poor prognosis and induces gastric cancer progression via AKT‐mTOR pathway

Wang

Cheng

Dai

et al. 2023

Molecular Carcinogenesis

View full text Add to dashboard Cite

Gastric cancer (GC) is among of the leading causes of cancer mortality worldwide. This is because many patients are diagnosed with advanced GC and postoperative radiotherapy and chemotherapy have also exhibited limited effects on GC. TYRO3 has been considered carcinogenic and a potential therapeutic target for GC. However, TYRO3 function and mechanism in GC remains elusive. The study results indicated that TYRO3 was aberrantly elevated in GC tissues and predicted poor prognosis. TYRO3 is closely associated with clinicopathological indicators in GC tissues such as lymph node metastasis, venous invasion, neural invasion, and the tumor‐node‐metastasis stage. In addition, TYRO3 expression levels are closely related to the AKT‐mTOR pathway in GC tissues. Moreover, the oncogenic role of TYRO3 was determined through in vitro and in vivo functional assays, and knockdown of the TYRO3 expression level in GC cell lines can effectively suppress the AKT‐mTOR pathway and inhibit tumor cell proliferation and migration. In conclusion, this study provides a theoretical basis for establishing the potential association and regulatory mechanism between TYRO3 and AKT‐mTOR and offers a new strategy for GC‐targeted therapy.

show abstract

Selective apoptotic and genotoxic effects of pomegranate peel extract against human hepatocellular carcinoma HepG2 cell line

Basal,

El-Sakka,

El-Sonousy

et al. 2024

ADV TRADIT MED (ADTM)

View full text Add to dashboard Cite

Tyro3 Targeting as a Radiosensitizing Strategy in Bladder Cancer through Cell Cycle Dysregulation

Cited by 4 publications

References 45 publications

TYRO3 promotes tumorigenesis and drug resistance in colorectal cancer by enhancing the epithelial-mesenchymal transition process

TYRO3 promotes tumorigenesis and drug resistance in colorectal cancer by enhancing the epithelial-mesenchymal transition process

Overexpression of TYRO3 indicates poor prognosis and induces gastric cancer progression via AKT‐mTOR pathway

Selective apoptotic and genotoxic effects of pomegranate peel extract against human hepatocellular carcinoma HepG2 cell line

Contact Info

Product

Resources

About